Overview
Special Survey for Long Term Application
Status:
Completed
Completed
Trial end date:
2007-03-31
2007-03-31
Target enrollment:
0
0
Participant gender:
All
All
Summary
This study is conducted in Japan. The aim of this study is to assess the incidence rate of adverse drug reactions (ADRs) when using somatropin (Norditropin®) for treatment of for achondroplasia without epiphyseal line closure under normal clinical practice conditions.Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Novo Nordisk A/S
Criteria
Inclusion Criteria:- Achondroplasia without epiphyseal line closure